{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:04:27Z","timestamp":1785297867506,"version":"3.55.0"},"reference-count":61,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gene\u2010based therapies show increasing promise for the treatment of neurologic disease. In 2016, nusinersen, an RNA\u2010based therapy, was approved for children with spinal muscular atrophy (SMA). Over 200 clinical trials have utilized gene therapy approaches for a host of neurodegenerative and neuromuscular disorders, including Alzheimer's disease (AD).\n                    <jats:sup>1<\/jats:sup>\n                    Delivering gene\u2010based therapies to the central nervous system (CNS) has raised safety concerns. As clinical trials utilizing gene therapy paradigms are undertaken and as approved therapies translate into clinics, a better understanding of safety issues and monitoring parameters is needed. We describe current therapeutic approaches for AD using gene\u2010based therapies such as adeno\u2010associated virus gene therapy and RNA interference by antisense oligonucleotides (ASOs) and undertake a review of medical safety considerations for existing AD gene therapy trials. We identify challenges in analyzing medical safety data currently available and provide guidelines for making this information more accessible and interpretable for the future.\n                  <\/jats:p>","DOI":"10.1002\/alz.71515","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:52:50Z","timestamp":1783666370000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety considerations of gene\u2010based therapies for Alzheimer's disease"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9306-9435","authenticated-orcid":false,"given":"Elizabeth A.","family":"Bevins","sequence":"first","affiliation":[{"name":"Alzheimer's Disease Cooperative Study (ADCS) University of California San Diego  La Jolla California USA"},{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-3957","authenticated-orcid":false,"given":"Gabriel C.","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study (ADCS) University of California San Diego  La Jolla California USA"},{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0187-213X","authenticated-orcid":false,"given":"Michelle A.","family":"Herman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study (ADCS) University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-0777","authenticated-orcid":false,"given":"John M.","family":"Ringman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Research Center Department of Neurology Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-2735","authenticated-orcid":false,"given":"Subhojit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"},{"name":"Department of Pathology University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-890X","authenticated-orcid":false,"given":"Matthew","family":"Shtrahman","sequence":"additional","affiliation":[{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-9352","authenticated-orcid":false,"given":"Judy","family":"Pa","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study (ADCS) University of California San Diego  La Jolla California USA"},{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-4538","authenticated-orcid":false,"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study (ADCS) University of California San Diego  La Jolla California USA"},{"name":"Department of Neurosciences University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm1212197910.3390\/jpm12121979"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jhered.a10565310.1093\/oxfordjournals.jhered.a105653"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.12.01610.1016\/j.ymgme.2008.12.016"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.69580810.3389\/fnagi.2021.695808"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/30255310.1086\/302553"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593\u2010020\u201000778\u2010110.1038\/s41593\u2010020\u201000778\u20101"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa170619810.1056\/nejmoa1706198"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm123910.1038\/nm1239"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.498310.1001\/jamaneurol.2023.4983"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa221564310.1056\/nejmoa2215643"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa170275210.1056\/nejmoa1702752"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa171679310.1056\/nejmoa1716793"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa220470510.1056\/nejmoa2204705"},{"key":"e_1_2_7_15_1","unstructured":"NCT03186989.Safety pharmacokinetics and pharmacodynamics of IONIS\u2010MAPTRx in patients with mild Alzheimer's disease.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT03186989"},{"key":"e_1_2_7_16_1","unstructured":"NCT05399888. A study to learn about the safety of BIIB080 injections and whether they can improve symptoms of participants with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia between 50 to 80 years of age.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05399888"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.02.02910.1016\/j.ymthe.2018.02.029"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.03.00710.1016\/j.omtn.2018.03.007"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010\u2010020\u201003834\u2010310.1007\/s11010\u2010020\u201003834\u20103"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.10.01510.1016\/j.ymthe.2023.10.015"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.97580310.3389\/fimmu.2022.975803"},{"key":"e_1_2_7_22_1","unstructured":"U.S. Food and Drug Administration.Approved cellular and gene therapy products. Accessed April 18 2025.https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/cellular\u2010gene\u2010therapy\u2010products\/approved\u2010cellular\u2010and\u2010gene\u2010therapy\u2010products"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.04.00910.1016\/j.jconrel.2023.04.009"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci1002011910.3390\/brainsci10020119"},{"key":"e_1_2_7_25_1","unstructured":"U.S. Food and Drug Administration. Human gene therapy for neurodegenerative diseases. Accessed April 18 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/human\u2010gene\u2010therapy\u2010neurodegenerative\u2010diseases"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.06710.1016\/j.jconrel.2023.01.067"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.301510.1002\/jgm.3015"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.5177210.1002\/acn3.51772"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.29139.bfs10.1089\/hum.2020.29139.bfs"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adm838610.1126\/science.adm8386"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.68580210.3389\/fneur.2021.685802"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.127210.1001\/jamaneurol.2021.1272"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","unstructured":"MillerR PaquetteJ BarkerA et\u00a0al.Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation.bioRxiv.2024.https:\/\/doi.org\/10.1101\/2024.06.06.59763910.1101\/2024.06.06.597639","DOI":"10.1016\/j.omtn.2024.102359"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.12.01010.1016\/j.omtn.2022.12.010"},{"key":"e_1_2_7_35_1","unstructured":"GENERATION HD2.A study to evaluate the safety biomarkers and efficacy of Tominersen compared with placebo in participants with prodromal and early manifest Huntington's disease: NCT05686551.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05686551"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc230040010.1056\/nejmc2300400"},{"key":"e_1_2_7_37_1","unstructured":"Gene Therapy for Alzheimer's Disease Clinical Trial. NCT00017940.2009. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT00017940"},{"key":"e_1_2_7_38_1","unstructured":"Encapsulated cell biodelivery of nerve growth factor to Alzheimer\u00b4s disease patients: NCT01163825.2010. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT01163825"},{"key":"e_1_2_7_39_1","unstructured":"CERE\u2010110 in subjects with mild to moderate Alzheimer's disease: NCT00087789.2022. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT00087789"},{"key":"e_1_2_7_40_1","unstructured":"Randomized controlled study evaluating CERE\u2010110 in subjects with mild to moderate Alzheimer's disease: NCT00876863.2020. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT00876863"},{"key":"e_1_2_7_41_1","unstructured":"A clinical trial of AAV2\u2010BDNF gene therapy in early Alzheimer's disease and mild cognitive impairment: NCT05040217.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05040217"},{"key":"e_1_2_7_42_1","unstructured":"Gene therapy for APOE4 homozygote of Alzheimer's disease: NCT03634007.2024. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT03634007"},{"key":"e_1_2_7_43_1","unstructured":"Long\u2010term follow\u2010up of gene therapy for APOE4 homozygote Alzheimer's disease: NCT05400330.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05400330"},{"key":"e_1_2_7_44_1","unstructured":"Evaluation of safety and tolerability of Libella Gene Therapy for Alzheimer's disease: AAV\u2010 hTERT. NCT04133454.2019. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT04133454"},{"key":"e_1_2_7_45_1","unstructured":"Study of safety tolerability pharmacodynamics and pharmacokinetics of NIO752 in early Alzheimer's disease participants: NCT05469360.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05469360"},{"key":"e_1_2_7_46_1","unstructured":"A trial evaluating the effect of NIO752 on tau synthesis measured by a process known as SILK: NCT06372821.2024. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT06372821"},{"key":"e_1_2_7_47_1","unstructured":"A study to evaluate the safety and tolerability of ALN\u2010APP in patients with EOAD: NCT05231785.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT05231785"},{"key":"e_1_2_7_48_1","unstructured":"A first\u2010in\u2010human study of LY3954068 in participants with early symptomatic Alzheimer's disease. NCT06297590.2025. Accessed June 27 2025.https:\/\/clinicaltrials.gov\/study\/NCT06297590"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/00033605110.1159\/000336051"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.09.00410.1016\/j.jalz.2013.09.004"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.023310.1001\/jamaneurol.2018.0233"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02326-3"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.330303710.1038\/sj.gt.3303037"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.10399710.1016\/j.cellimm.2019.103997"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.03.02010.1016\/j.neuron.2019.03.020"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.16710.1089\/hum.2020.167"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.08710.1089\/hum.2016.087"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.10110.1038\/gt.2012.101"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.21010.1038\/mt.2014.210"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa190090710.1056\/nejmoa1900907"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.23810.1089\/hum.2013.238"},{"key":"e_1_2_7_62_1","unstructured":"Help to shape the MedDRA terminology. MedDRA. Accessed April 11 2025.https:\/\/www.meddra.org\/"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:28:37Z","timestamp":1785295717000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/alz.71515"],"URL":"https:\/\/doi.org\/10.1002\/alz.71515","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71515"}}